SCHEMBL7102290

SCHEMBL7102290

CC(=S)[C@H](C)C(=O)NC(C(=O)NCCc1ccccc1)C(=O)NCCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
TSHR P16473 1/20 0.51
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
CYP2D6 P10635 1/20 0.50
POLB P06746 1/20 0.50
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
ALDH1A1 P00352 2/20 0.49
ALOX12 P18054 2/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
ANPEP P15144 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 1/20 0.47
IDO1 P14902 1/20 0.46
MGLL Q99685 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7099866 1.00 KMT2A (0.51) KMT2AMEN1TSHRCYP2C9CYP2C19
SCHEMBL7099870 1.00 KMT2A (0.51) KMT2AMEN1TSHRCYP2C9CYP2C19
SCHEMBL7102063 0.87 KMT2A (0.49) KMT2AMEN1TSHRCYP2C9CYP2C19
SCHEMBL7102068 0.87 KMT2A (0.49) KMT2AMEN1TSHRCYP2C9CYP2C19
SCHEMBL7097755 0.84 MMP8 (0.54) KMT2AMEN1TSHRPOLBRAB9A
SCHEMBL7104285 0.84 MMP8 (0.52) KMT2AMEN1TSHRPOLBRAB9A
SCHEMBL7104280 0.84 MMP8 (0.52) KMT2AMEN1TSHRPOLBRAB9A
SCHEMBL7097759 0.84 MMP8 (0.54) KMT2AMEN1TSHRPOLBRAB9A
SCHEMBL7102221 0.82 POLB (0.49) KMT2AMEN1TSHRCYP2C9CYP2C19
SCHEMBL7098602 0.82 KMT2A (0.55) KMT2AMEN1TSHRCYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1140818-B1 AMIDOMALONAMIDES AND THEIR USE AS INHIBITORS OF MATRIX METALLOPROTEINASE AVENTIS PHARMA INC (US) 2003-09-10 EP disclosed
US-6329550-B1 FOR THERAPY OF EMPHYSEMA, OSTEOPOROSIS, RHEUMATOID ARTHRITIS AND NEOPLASTIC DISEASES AVENTIS PHARMACEUTICALS INC. 2001-12-11 US disclosed